Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

upadacitinib MeSH Supplementary Concept Data 2025


MeSH Supplementary
upadacitinib
Unique ID
C000613732
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000613732
Entry Term(s)
(3S,4R)-3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide
ABT-494
Rinvoq
Pharm Action
Antirheumatic Agents
Janus Kinase Inhibitors
Registry Numbers
4RA0KN46E0
Heading Mapped to
*Heterocyclic Compounds, 3-Ring
Frequency
181
Note
a JAK-1 inhibitor; for treatment of rheumatoid arthritis
Source
Biodrugs. 2016 Oct;30(5):407-19.
Date of Entry
2017/01/27
Revision Date
2019/08/28
upadacitinib Preferred
ABT-494 Narrower
Rinvoq Related
page delivered in 0.004s